Yao Hong-Xia, Huang Li, Lin Li-E, Wu Cong-Ming, Wang Hua, Chen Wen-Ting, Fu Xiang-Jun, Ding Yi-Peng
Department Hematology of Hainan Provincial People's Hospital, Haikou 570311, China. Email:
Zhonghua Yi Xue Za Zhi. 2010 Jan 26;90(4):253-5.
To observe the influence of the plasma thromboxane B2 (TXB2), 6-keto-PGF1alpha, CD62P and PAC-1 and Thrombus in patients with primary thrombocytosis (ET). To observe the effect of sodium ozagrel to prevent and treat thrombosis in patients with ET.
The subjects including 48 patients with ET. All patients were measured the plasma TXB2, 6-keto-PGF1alpha, CD62P and PAC-1 before and after treatment with or without sodium ozagrel.
The plasma levels of CD62P, PAC-1, TXB2, 6-keto-PGF1alpha and TXA2/PGI2 in the patients with ET were significantly higher than the normal people (P < 0.01). The levels of CD62P, PAC-1, TXB2, TXB2/6-keto-PGF1alpha in patients with treatment of sodium ozagrel were higher than patients without treatment of sodium ozagrel (P < 0.01). The plasma levels of CD62P, PAC-1 and TXA2/PGI2 in patients with treatment of sodium ozagrel and that in normal people had no significant distinction (P < 0.01). All the index of conventional therapy group were higher than normal people (P < 0.01) but had no significant distinction with the patients before conventional treating. The incidence of thrombus in patients treated with sodium ozagrel was lower than patients treated without sodium ozagrel (P < 0.05).
With the treatment of sodium ozagrel in patients with ET, the CD62P, PAC-1, TXB2 and TXA2/PGI2 of plasma could be decreased. And the incidence of thrombus was decreased.
观察原发性血小板增多症（ET）患者血浆血栓素B2（TXB2）、6-酮-前列腺素F1α（6-keto-PGF1α）、CD62P和血小板激活复合物（PAC-1）及血栓情况。观察奥扎格雷钠防治ET患者血栓形成的作用。
选取48例ET患者。所有患者在使用或未使用奥扎格雷钠治疗前后检测血浆TXB2、6-keto-PGF1α、CD62P和PAC-1。
ET患者血浆CD62P、PAC-1、TXB2、6-keto-PGF1α及血栓素A2/前列环素（TXA2/PGI2）水平显著高于正常人（P<0.01）。使用奥扎格雷钠治疗患者的CD62P、PAC-1、TXB2、TXB2/6-keto-PGF1α水平高于未使用奥扎格雷钠治疗患者（P<0.01）。使用奥扎格雷钠治疗患者的血浆CD62P、PAC-1及TXA2/PGI2水平与正常人无显著差异（P<0.01）。常规治疗组各项指标均高于正常人（P<0.01），但与常规治疗前患者无显著差异。使用奥扎格雷钠治疗患者的血栓发生率低于未使用奥扎格雷钠治疗患者（P<0.05）。
ET患者使用奥扎格雷钠治疗后，血浆CD62P、PAC-1、TXB2及TXA2/PGI2水平可降低，血栓发生率降低。
